AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
AN2 Therapeutics Inc ANTX
$4.88
▼ -0.20%
($-0.01)
Open
$4.91
Prev Close
$4.89
Day Range
$4.71 – $4.95
52W Range
$1.00 – $7.19
Market Cap
$184.15M
Beta
-0.99
EPS (TTM)
$-1.07
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-03-25 |
| Shares Out. | 36,020,000 |
| Website | an2therapeutics.com/ ↗ |
| Phone | 16503319090 |
| Employees | 21 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$8.2M |
| Free Cash Flow | -$30.7M |
| Total Assets | $81.7M |
| Total Liabilities | $5.8M |
| Equity | $75.9M |
About AN2 Therapeutics Inc
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
AN2 Therapeutics Inc is a publicly traded company under the ticker symbol ANTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)